We're so grateful that he's walking and talking, at his own pace
What the Clinical Evidence Shows The data supporting GLP-1 medications dual effect on weight and alcohol consumption is growing rapidly across both preclinical and human studies
In animal models, caloric restriction is associated with more efficient skin wound repair and regeneration, possibly via enhanced vascular supply and growth factor signaling in the dermis
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
Wait until the flavor is completely gone
Tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist, represents a newer agent with robust weight loss efficacy
